Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.

"Declaration of interests J.T., H.T. and A.T. have participated in research projects funded by grants from Janssen‐Cilag and Eli Lilly to their employing institution. H.T. reports personal fees from Janssen‐Cilag. J.T. reports personal fees from the Finnish Medicines Agency (Fimea), the European Medicines Agency (EMA), Eli Lilly, Janssen‐Cilag, Lundbeck and Otsuka, is a member of advisory board for Lundbeck and has received grants from the Stanley Foundation and Sigrid Jusélius Foundation. M.L. is a board member of Genomi Solutions Ltd and Nursie Health Ltd and has received honoraria from Sunovion Ltd and Orion Pharma Ltd. Janssen‐Cilag and Otsuka Ltd and research funding from the Finnish Medical Foundation and Emil Aaltonen Foundation."

"This study was funded by the Finnish Ministry of Social Affairs and Health through the developmental fund for Niuvanniemi Hospital. M.L. was partly funded by personal grants from the Finnish Medical Foundation and Emil Aaltonen Foundation. The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding authors had full access to all of the data and the final responsibility to submit for publication."